Hypha Labs Reports No Revenue and Significant Financial Challenges in Latest 10-Q Filing

Hypha Labs, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded no revenue for both the three and nine months ended June 30, 2026, maintaining a consistent trend from the previous fiscal period. Operating expenses for the three months decreased to $95,953 from $536,027 in the same period last year, while for the nine months, they fell to $991,366 from $2,510,453. The net loss for the quarter was $304,757, a reduction from $562,023 in the prior year, and for the nine months, the loss was $1,347,509 compared to $2,543,486 in 2025.

The company’s balance sheet reflects a substantial decline in total assets, which decreased to $68,327 from $409,218 as of September 30, 2025. Current assets dropped significantly, primarily due to a reduction in cash, which fell to $5,110 from $38,118. Current liabilities increased to $1,592,630 from $1,118,955, driven by higher accounts payable and accrued expenses. The accumulated deficit also widened to $24,996,836 from $23,649,327, indicating ongoing financial strain.

Strategically, Hypha Labs has shifted its focus following the sale of its subsidiary, Digipath Labs, in February 2024. The company is now concentrating on the development and commercialization of the Hypha Micropearl bioreactor, a device designed to produce nutritionally beneficial mushrooms at home. The company plans to conduct testing and design improvements over the next nine months, with an aim to launch the product by late 2026. However, there is no assurance that this timeline will be met.

Operationally, Hypha Labs has seen a decrease in employee headcount and engagement metrics, reflecting its transition away from its previous business model. The company has paused its Regulation A offering and does not expect to raise additional funds in the near term, which raises concerns about its ability to sustain operations. As of June 30, 2026, the company had negative working capital of $1,577,350, which raises substantial doubt about its ability to continue as a going concern.

Looking ahead, Hypha Labs intends to seek additional funding through equity or debt securities to support the development of its bioreactor and to explore potential acquisition targets. However, the company acknowledges the uncertainty surrounding its ability to secure necessary funds, which could impact its operational continuity. The management's forward-looking statements emphasize the need for strategic financial planning to navigate the challenges ahead.